16 May
Nora Ventosa, the Scientific Director of NANBIOSIS U6 of Biomateria[...]
12 May
Conventional chemotherapeutics used to fight cancer promote off-target damage in[...]
Integrated solutions to advanced challenges faced by biomedical researchers in nanomedicine, tissue engineering and regenerative medicine, diagnostic and medical device, that includes design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of these bio-/nanomaterials, tissues and medicals devices from a physic-chemical, functional, toxicological and biological point of view up to preclinical validation.
Contact us
Due to the current pandemic outbreak of COVID-19, caused by the SARS-CoV-2 virus, knowledge about the virus characteristics and the development of its possible diagnostic, treatment and prophylactic devices and systems are high priority in all research institutions worldwide.
NANBIOSIS assigns high priority to the projects related to the SARS-CoV-2 virus offering preferential access. For that purpose, A “COVID-19 Rapid Access” call has been established, valid through the years 2020-22. Urgent procedure will be applied to review and admission of the proposals.
Customized design and production services of biological molecules for Tissue Engineering, Intelligent Devices, Implants, and specially Therapeutic Nanoconjugates and Biosensors by providing for applications such as:
− Therapeutic agents
− Targeting
− Surfaces functionalization: Tissue engineering/scaffolds & biosensors
Recombinant proteins
Antibodies and Haptens
Custom peptides and post modification
Oligonucleotides
Anti-peptide Antibodies
Protein-only nanomaterial platform for biomedical purposes
Supply nanomaterials for applications in Nanomedicine: therapy, drug delivery, contras agents (MRI, fluorescence) & theranostic
Nanoparticles
Pure active pharmaceutical ingredients with controlled nansotructure
Supply nanoconjugates for applications in Nanomedicine: therapy, contras agents (MRI) & theranostic)
Bioconjugation
Nanoconjugation
Micro and nanoencapsulation
Preclinical characterization of nanomedicines including physicochemical properties, in vitro and in vivo biological properties (immunology, toxicology an efficacy with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions
Complete cascade characterization
Physicochemical characterization
In vitro characterization
In vivo characterization
Development of prototypes and biosensing devices for diagnostic, production of bioreceptor against identified biomarkers an detection of biomarkers for diagnostic, follow-up and prognostic of diseases by NMR spectroscopies in biofluids and tissues.
Development and validation of biosensor
Anti-peptide Antibodies
Devices
Quatintifaction of Biomarker by NMR
In vivo validation of contrast agents and development of nanoconjugates as contrast agents for MRI and fluorescence.
Nanoparticles
Contrast Agents for MRI & OTC
Validation of NPs for glioma
Validation of Contrast Agents for MRI
Nanocojugates for fluorescence
Nanocojugates for MRI
Design and production of scaffolds for tissue engineering
Scaffolds
Functionalized scaffolds
Preclinical validation of biomaterials including surface and mechanical characterization and in vitro and in vivo biological properties with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions
Preclinical validation
Surface and mechanical characterization
Adhesion of bateria: biofilms
Biocampatibility
In vivo Validation of medical devices for determined applications in different animal models
Contact us
Platform Unit 1.Biomolecules
|
Platform Unit 2.Biomaterials
|
Platform Unit 3.Preclinical
|
||
|
Units
Scientists linked to ICTS
Projects since 2008
Services since 2008
Publications since 2008
M€ investment